Overview

Envarsus on the Effect of Total Tacrolimus Dose/Trough Level Ratio on Renal Function (eGFR) in Kidney Transplantation

Status:
Active, not recruiting

Trial end date:
2021-07-01

Target enrollment:

Participant gender:

Summary

This is a one year, prospective, randomized, open-label trial examining once versus twice daily tacrolimus dosing regimen using two preparations, extended-release Tacrolimus (Envarsus XR) versus twice daily Tacrolimus (Prograf). It will examine kidney function between the two groups using estimated glomerular filtration rate (eGFR) and also examine one-year kidney outcomes, including graft loss and patient death. Patients will be followed for up to 1 year during the open-label study period.

Phase:

Phase 4

Details

Lead Sponsor:

Columbia University

Collaborator:

Veloxis Pharmaceuticals

Treatments:

Tacrolimus